Evidence map›Paper›PMID 25395615›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2015

Smooth muscle cell deletion of low-density lipoprotein receptor-related protein 1 augments angiotensin II-induced superior mesenteric arterial and ascending aortic aneurysms.

Frank M Davis, Debra L Rateri, Anju Balakrishnan, Deborah A Howatt, Dudley K Strickland, Selen C Muratoglu, Christopher M Haggerty, Brandon K Fornwalt, Lisa A Cassis, Alan Daugherty

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Angiotensin II Induces Abdominal Aortic Branch Aneurysms inArteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Angiotensinogen as a Therapeutic Target for Cardiovascular and Metabolic Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Genetic Variation inJournal of cardiovascular development and disease · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Frank M DavisFrom the Saha Cardiovascular Research Center (F.M.D., D.L.R., A.B., D.A.H., C.M.H., B.K.F., A.D.), Department of Pediatrics (B.K.F.), Department of Pharmacology and Nutritional Sciences (L.A.C.), University of Kentucky, Lexington; and Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore (D.K.S., S.C.M.).
Debra L RateriFrom the Saha Cardiovascular Research Center (F.M.D., D.L.R., A.B., D.A.H., C.M.H., B.K.F., A.D.), Department of Pediatrics (B.K.F.), Department of Pharmacology and Nutritional Sciences (L.A.C.), University of Kentucky, Lexington; and Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore (D.K.S., S.C.M.).
Anju BalakrishnanFrom the Saha Cardiovascular Research Center (F.M.D., D.L.R., A.B., D.A.H., C.M.H., B.K.F., A.D.), Department of Pediatrics (B.K.F.), Department of Pharmacology and Nutritional Sciences (L.A.C.), University of Kentucky, Lexington; and Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore (D.K.S., S.C.M.).
Deborah A HowattFrom the Saha Cardiovascular Research Center (F.M.D., D.L.R., A.B., D.A.H., C.M.H., B.K.F., A.D.), Department of Pediatrics (B.K.F.), Department of Pharmacology and Nutritional Sciences (L.A.C.), University of Kentucky, Lexington; and Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore (D.K.S., S.C.M.).
Dudley K StricklandFrom the Saha Cardiovascular Research Center (F.M.D., D.L.R., A.B., D.A.H., C.M.H., B.K.F., A.D.), Department of Pediatrics (B.K.F.), Department of Pharmacology and Nutritional Sciences (L.A.C.), University of Kentucky, Lexington; and Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore (D.K.S., S.C.M.).
Selen C MuratogluFrom the Saha Cardiovascular Research Center (F.M.D., D.L.R., A.B., D.A.H., C.M.H., B.K.F., A.D.), Department of Pediatrics (B.K.F.), Department of Pharmacology and Nutritional Sciences (L.A.C.), University of Kentucky, Lexington; and Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore (D.K.S., S.C.M.).
Christopher M HaggertyFrom the Saha Cardiovascular Research Center (F.M.D., D.L.R., A.B., D.A.H., C.M.H., B.K.F., A.D.), Department of Pediatrics (B.K.F.), Department of Pharmacology and Nutritional Sciences (L.A.C.), University of Kentucky, Lexington; and Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore (D.K.S., S.C.M.).
Brandon K FornwaltFrom the Saha Cardiovascular Research Center (F.M.D., D.L.R., A.B., D.A.H., C.M.H., B.K.F., A.D.), Department of Pediatrics (B.K.F.), Department of Pharmacology and Nutritional Sciences (L.A.C.), University of Kentucky, Lexington; and Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore (D.K.S., S.C.M.).
Lisa A CassisFrom the Saha Cardiovascular Research Center (F.M.D., D.L.R., A.B., D.A.H., C.M.H., B.K.F., A.D.), Department of Pediatrics (B.K.F.), Department of Pharmacology and Nutritional Sciences (L.A.C.), University of Kentucky, Lexington; and Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore (D.K.S., S.C.M.).
Alan DaughertyFrom the Saha Cardiovascular Research Center (F.M.D., D.L.R., A.B., D.A.H., C.M.H., B.K.F., A.D.), Department of Pediatrics (B.K.F.), Department of Pharmacology and Nutritional Sciences (L.A.C.), University of Kentucky, Lexington; and Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore (D.K.S., S.C.M.). Alan.Daugherty@uky.edu.
University of Maryland, Baltimore · US

Funding

The role of IKKß in linking obesity to adipose tissue inflammation and adipogeneP20GM103527 · NIGMS · UNIVERSITY OF KENTUCKY · PI MORRIS, ANDREW J · 2012 to 2017
$13.7M
Sex Differences in Angiotensin-Induced Vascular DiseasesR01HL107326 · NHLBI · UNIVERSITY OF KENTUCKY · PI CASSIS, LISA A · 2012 to 2019
$3.7M
A High-Field Small Animal MR Imager for Biomedical ResearchS10RR029541 · NCRR · UNIVERSITY OF KENTUCKY · PI SMITH, CHARLES DENNIS · 2010 to 2010
$3.1M
Mechanisms of thoracic aortic aneurysmsR01HL107319 · NHLBI · UNIVERSITY OF KENTUCKY · PI DAUGHERTY, ALAN · 2012 to 2015
$2.1M
Role of Lipoprotein Receptors in Venous ThrombosisR01HL114379 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI STRICKLAND, DUDLEY K. · 2012 to 2016
$1.9M
Mechanisms by which LRP1 Protects the VasculatureR01HL120388 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI STRICKLAND, DUDLEY K. · 2014 to 2016
$1.1M
NCRR NIH HHS S10 RR029541NHLBI NIH HHS HL107319NHLBI NIH HHS HL114379NHLBI NIH HHS HL120388NHLBI NIH HHS R01 HL107319NHLBI NIH HHS R01 HL107326NHLBI NIH HHS R01 HL114379NHLBI NIH HHS R01 HL120388NIGMS NIH HHS P20 GM103527
6 · The paper itself

Abstract

objectiveLow-density lipoprotein receptor-related protein 1 (LRP1), a multifunctional protein involved in endocytosis and cell signaling pathways, leads to several vascular pathologies when deleted in vascular smooth muscle cells (SMCs). The purpose of this study was to determine whether LRP1 deletion in SMCs influenced angiotensin II-induced arterial pathologies. APPROACH AND

resultsLRP1 protein abundance was equivalent in selected arterial regions, but SMC-specific LRP1 depletion had no effect on abdominal and ascending aortic diameters in young mice. To determine the effects of LRP1 deficiency on angiotensin II vascular responses, SMC-specific LRP1 (smLRP1(+/+)) and smLRP1-deficient (smLRP1(-/-)) mice were infused with saline, angiotensin II, or norepinephrine. Several smLRP(-/-) mice died of superior mesenteric arterial (SMA) rupture during angiotensin II infusion. In surviving mice, angiotensin II profoundly augmented SMA dilation in smLRP1(-/-) mice. SMA dilation was blood pressure dependent as demonstrated by a similar response during norepinephrine infusion. SMA dilation was also associated with profound macrophage accumulation, but minimal elastin fragmentation. Angiotensin II infusion led to no significant differences in abdominal aorta diameters between smLRP1(+/+) and smLRP1(-/-) mice. In contrast, ascending aortic dilation was exacerbated markedly in angiotensin II-infused smLRP1(-/-) mice, but norepinephrine had no significant effect on either aortic region. Ascending aortas of smLRP1(-/-) mice infused with angiotensin II had minimal macrophage accumulation but significantly increased elastin fragmentation and mRNA abundance of several LRP1 ligands including MMP-2 (matrix metalloproteinase-2) and uPA (urokinase plasminogen activator).

conclusionssmLRP1 deficiency had no effect on angiotensin II-induced abdominal aortic aneurysm formation. Conversely, angiotensin II infusion in smLRP1(-/-) mice exacerbated SMA and ascending aorta dilation. Dilation in these 2 regions had differential association with blood pressure and divergent pathological characteristics.

Indexed as

Angiotensin IIGene DeletionAneurysmAnimalsAorta, AbdominalAortic AneurysmAortic Aneurysm, AbdominalArterial PressureCells, CulturedDilatation, PathologicDisease Models, AnimalElastinLigandsLow Density Lipoprotein Receptor-Related Protein-1MacrophagesMaleAngiotensin IIElastinLigandsLow Density Lipoprotein Receptor-Related Protein-1Lrp1 protein, mouseMatrix Metalloproteinase 2Mmp2 protein, mouseNorepinephrineReceptors, LDLRNA, MessengerTumor Suppressor ProteinsUrokinase-Type Plasminogen Activatorangiotensin IIaortic aneurysmLRP1 protein, mouse

Identifiers

PMID25395615
PMCPMC4332619
OpenAlexW2132519011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.